Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.

Reimbursement Issues in Prostate Cancer, Part II

December 12th 2012

Reimbursement Issues in Prostate Cancer, Part I

December 12th 2012

Dr. Shore on the Management of Patients with CRPC

December 12th 2012

Dr. Shore Discusses Therapy Combination in CRPC

December 12th 2012

Management of Patients with Advanced Prostate Cancer

December 12th 2012

Dr. Shore Reviews Emerging Therapies in Prostate Cancer

December 12th 2012

Emerging Therapies in Prostate Cancer

December 12th 2012

Treatments for Post-Docetaxel Prostate Cancer, Part II

December 12th 2012

Treatments for Post-Docetaxel Prostate Cancer, Part I

December 12th 2012

NCCN Guidelines for Advanced Prostate Cancer

December 12th 2012

Immunotherapy in Advanced Prostate Cancer, Part II

December 12th 2012

Immunotherapy in Advanced Prostate Cancer, Part I

December 12th 2012

Managing ADT-Associated Skeletal-Related Events

December 12th 2012

Prostate Cancer Management: Introduction and Overview

December 12th 2012

Rationalizing Treatment and Coverage Decisions With Predictive Biomarkers

December 11th 2012

Predictive biomarkers are beginning to help physicians assign value to associated therapies in terms of likelihood of benefit and benefit-to-risk profiles for individual patients.

FDA Approves Earlier Use of Abiraterone Acetate

December 10th 2012

The FDA has approved abiraterone acetate in combination with prednisone prior to chemotherapy for the treatment of men with metastatic castration-resistant prostate cancer.

Legal Considerations With Accountable Care Organizations

November 30th 2012

Oncologists should be aware that the need to refer patients between ACO members can raise legal issues for practices and should consider two key laws before participating.

FDA Approves Cabozantinib for Medullary Thyroid Cancer

November 29th 2012

The FDA approved cabozantinib, a multi-targeted tyrosine kinase inhibitor, for the treatment of metastatic medullary thyroid cancer.

Can Practices Successfully Dispense Oral Anticancer Agents In-House?

November 16th 2012

In-house dispensing of oral agents in the community oncology setting may provide a safer and more reliable and convenient way for patients to receive their medications.

Treatment and Cost Implications of Pertuzumab

November 15th 2012

Pertuzumab, a new HER2-positive breast cancer drug, is being launched at a 31% premium to the price of trastuzumab.